Drug Profile
LJPC 1010
Alternative Names: LJPC-1010Latest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator La Jolla Pharmaceutical Company
- Class Polysaccharides
- Mechanism of Action Galectin 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Non-alcoholic steatohepatitis